Creatine, a naturally occurring compound found in muscle and brain tissue, was evaluated in a large Phase 3 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). The rationale was based on the hypothesis that supplementing energy metabolism might protect motor neurons from the energetic dysfunction observed in ALS[@creatine2006].
Creatine is a naturally occurring amino acid derivative that plays a critical role in cellular energy homeostasis. Through its conversion to phosphocreatine, it serves as a rapidly mobilizable reserve of high-energy phosphate groups for the regeneration of ATP. This function is particularly important in tissues with high energy demands, such as skeletal muscle and brain.
Trial Details
NCT Number: NCT00145574 (also associated with sodium phenylbutyrate trial)
Phase: Phase 3
Status: Completed (Results published)
Sponsor: National Institutes of Health (NIH), ALS Association
Drug: Creatine monohydrate
Dosage: 10 grams daily (5g twice daily)
Patient Population: Adults with clinically definite or probable ALS (El Escorial criteria)
Duration: 12 months
Enrollment: 1100 patients (largest ALS trial at the time)
Background and Rationale
Energy Dysfunction in ALS
Multiple lines of evidence support the role of energy dysfunction in ALS:
...
Overview
Creatine, a naturally occurring compound found in muscle and brain tissue, was evaluated in a large Phase 3 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). The rationale was based on the hypothesis that supplementing energy metabolism might protect motor neurons from the energetic dysfunction observed in ALS[@creatine2006].
Creatine is a naturally occurring amino acid derivative that plays a critical role in cellular energy homeostasis. Through its conversion to phosphocreatine, it serves as a rapidly mobilizable reserve of high-energy phosphate groups for the regeneration of ATP. This function is particularly important in tissues with high energy demands, such as skeletal muscle and brain.
Trial Details
NCT Number: NCT00145574 (also associated with sodium phenylbutyrate trial)
Phase: Phase 3
Status: Completed (Results published)
Sponsor: National Institutes of Health (NIH), ALS Association
Drug: Creatine monohydrate
Dosage: 10 grams daily (5g twice daily)
Patient Population: Adults with clinically definite or probable ALS (El Escorial criteria)
Duration: 12 months
Enrollment: 1100 patients (largest ALS trial at the time)
Background and Rationale
Energy Dysfunction in ALS
Multiple lines of evidence support the role of energy dysfunction in ALS:
Mitochondrial Abnormalities: Reduced Complex I and IV activity in ALS spinal cord
Metabolic Changes: Altered glucose metabolism in ALS patients
Muscle Energy Deficit: Reduced phosphocreatine in ALS muscle
Bioenergetic Crisis: Progressive decline in cellular energy reserves
Creatine as Energy Supplement
Creatine supplementation has been shown to:
Increase muscle phosphocreatine stores
Improve exercise capacity in healthy subjects
Protect against excitotoxicity in vitro
Have neuroprotective effects in animal models
Preclinical Evidence
In the SOD1 G93A mouse model of ALS:
Creatine supplementation improved survival
Enhanced motor performance
Reduced motor neuron loss
Decreased markers of oxidative stress
These preclinical findings provided the rationale for clinical testing in human ALS.
Mechanism of Action
Creatine supports cellular energy through multiple mechanisms:
Energy Metabolism
Phosphocreatine Formation: Creatine combines with ATP to form phosphocreatine via creatine kinase[@creatine]
ATP Regeneration: Facilitates rapid regeneration of ATP from ADP
Cellular Energy Reserve: Acts as an energy buffer during high-demand periods
PCr Shuttle: Transfers energy from mitochondria to cytosol
Neuroprotective Effects
Mitochondrial Function: Supports mitochondrial energy production